Get the Stockscreener App
125.88
20.01%
-31.48
Glaukos Corporation stock is traded at $125.88, with a volume of 4.14M.
It is down -20.01% in the last 24 hours and down -21.00% over the past month.
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
See More
Previous Close:
$157.36
Open:
$141.35
24h Volume:
4.14M
Relative Volume:
6.91
Market Cap:
$6.92B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-42.53
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-17.83%
1M Performance:
-21.00%
6M Performance:
-3.17%
1Y Performance:
+35.66%
1-Day Range:
$124.95
$142.95
1-Week Range:
$124.95
$161.78
52-Week Range:
$83.90
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
125.88 | 6.92B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos Corporation (NYSE:GKOS) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Glaukos Reports Record Sales Growth in Fourth Quarter of 2024, Announces 2025 Guidance - Vision Monday
Glaukos Q4 2024 Earnings Preview - MSN
Glaukos Corp. Reports Record Sales in Earnings Call - TipRanks
Glaukos Corp earnings missed by $0.02, revenue topped estimates - Investing.com India
Earnings call transcript: Glaukos Corp Q4 2024 sees revenue rise but EPS miss - Investing.com Nigeria
Truist maintains buy on Glaukos stock, price target steady at $185 By Investing.com - Investing.com South Africa
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline - MSN
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition - Benzinga
Truist maintains buy on Glaukos stock, price target steady at $185 - Investing.com
BTIG cuts Glaukos stock price target to $155 from $157 By Investing.com - Investing.com Nigeria
Glaukos Corporation (NYSE:GKOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Glaukos price target raised to $160 from $153 at Wells Fargo - TipRanks
BTIG cuts Glaukos stock price target to $155 from $157 - Investing.com UK
Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... - Yahoo Finance
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results - BioSpace
Glaukos Corporation Reports Strong 2024 Financial Results - TipRanks
Insider Selling: Glaukos Co. (NYSE:GKOS) Insider Sells 3,416 Shares of Stock - MarketBeat
Why Glaukos Stock is Soaring: Key Insights - TipRanks
Glaukos: Q4 Earnings Snapshot - Thehour.com
Glaukos Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos shares tumble 12% on wider-than-feared Q4 loss - Investing.com
Glaukos shares tumble 12% on wider-than-feared Q4 loss By Investing.com - Investing.com Australia
Glaukos Q4 Non-GAAP Loss Narrows, Sales Rise -February 20, 2025 at 04:37 pm EST - Marketscreener.com
Glaukos: Q4 Earnings Snapshot -February 20, 2025 at 05:52 pm EST - Marketscreener.com
Glaukos Reports Record Sales and Positive Revenue Outlook - TipRanks
Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q4 Loss $-0.40 Per Share, vs. FactSet Est of $-0.38 - Marketscreener.com
What To Expect From Glaukos Corp (GKOS) Q4 2024 Earnings - Yahoo Finance
Glaukos (NYSE:GKOS) Upgraded by Mizuho to Outperform Rating - MarketBeat
Glaukos Co. (NYSE:GKOS) Stock Holdings Trimmed by New York State Common Retirement Fund - MarketBeat
Glaukos Co. (NYSE:GKOS) Shares Sold by Peregrine Capital Management LLC - MarketBeat
Glaukos chief development officer Navratil sells $502,630 in stock - Investing.com India
Glaukos Stock Soars on Promising iDose Outlook - TipRanks
Mizuho Upgrades Glaukos (GKOS) - Nasdaq
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Glaukos rises after Mizuho upgrades rating to 'outperform' - TradingView
What to Expect From These 3 MedTech Stocks This Earnings Season? - Yahoo Finance
Allspring Global Investments Holdings LLC Lowers Position in Glaukos Co. (NYSE:GKOS) - MarketBeat
Truist maintains Buy on Glaukos stock with $185 target - MSN
Truist maintains Buy on Glaukos stock with $185 target By Investing.com - Investing.com Australia
What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings - Nasdaq
Legato Capital Management LLC Boosts Stock Holdings in Glaukos Co. (NYSE:GKOS) - MarketBeat
(GKOS) Investment Report - Stock Traders Daily
Glaukos (GKOS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now - MSN
Glaukos Co. (NYSE:GKOS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Glaukos (GKOS) Expected to Announce Earnings on Thursday - Defense World
Glaukos Corp. to Host Earnings Call - ACCESS Newswire
Peering Into Glaukos's Recent Short Interest - Benzinga
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):